Empowered Funds LLC Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Empowered Funds LLC increased its Teva stake by 1,146.4% during the first quarter, owning 37,430 shares valued at approximately $1.13 million. Institutional investors collectively hold 54.05% of Teva’s stock.
• Teva shares opened at $36.78, near their 52-week high of $37.39. The company reported quarterly revenue of $4.14 billion and $0.02 in EPS, while analysts expect $1.96 in full-year EPS.
• Analysts remain broadly bullish, with nine Buy ratings and one Hold rating. Teva has a “Moderate Buy” consensus and an average price target of $42.22, though an executive recently sold 106,563 shares.

Empowered Funds LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 1,146.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,430 shares of the company's stock after buying an additional 34,427 shares during the period. Empowered Funds LLC's holdings in Teva Pharmaceutical Industries were worth $1,127,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Aster Capital Management DIFC Ltd acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at about $25,000. Cornerstone Planning Group LLC grew its position in shares of Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock worth $27,000 after buying an additional 755 shares in the last quarter. Allworth Financial LP grew its position in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after buying an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock worth $32,000 after buying an additional 345 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Teva Pharmaceutical Industries by 567.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company's stock worth $42,000 after buying an additional 1,134 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $36.78 on Monday. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. Teva Pharmaceutical Industries Ltd. has a 1-year low of $17.33 and a 1-year high of $37.39. The stock has a market cap of $42.87 billion, a PE ratio of 61.31, a price-to-earnings-growth ratio of 3.93 and a beta of 0.86. The firm has a fifty day moving average price of $33.52 and a 200 day moving average price of $32.99.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The company had revenue of $4.14 billion for the quarter. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.96 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an "overweight" rating in a research report on Thursday, April 30th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a report on Thursday, April 30th. Truist Financial boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, April 30th. Finally, Weiss Ratings raised Teva Pharmaceutical Industries from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and a consensus price target of $42.22.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares of the company's stock, valued at $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source